8-K 1 v138532_8k.htm Unassociated Document
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): January 28, 2009
 
 
CardioVascular BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware
000-51172
33-0795984
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
 
1635 Village Center Circle, Suite 250
  
Las Vegas, Nevada
89134
(Address of Principal Executive Offices)
(Zip Code)
 
Registrant’s telephone number, including area code: 702-839-7200
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 


Dr. Thomas J. Stegmann resigned from the Board of Directors of the Company on January 28, 2009, which includes resignation as a member of the Nominating Committee and Conflicts Resolution Committee.  Additionally, he resigned from the title of Chief Medical Officer.

Dr. Stegmann’s reasons for his resignation are included in his letter dated January 28, 2009, a true and correct copy of which is attached hereto as Exhibit 17.

ITEM 9.01 Financial Statements and Exhibits

(d)
Exhibits
 
 
17
Letter from Dr. Thomas J. Stegmann resigning from the Board of Directors of the Company and from the title of Chief Medical Officer.

 
2
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
CARDIOVASCULAR BIOTHERAPEUTICS, INC.
 
  
 
  
 
  
Date: February 3, 2009
By:  
/s/ Mickael A. Flaa
 
Mickael A. Flaa
 
Chief Financial Officer
 
 
3
 
 
EXHIBIT INDEX

Exhibit
  
Number
Description
   
17
 
Letter from Dr. Thomas J. Stegmann resigning from the Board of Directors of the Company and from the title of Chief Medical Officer.
 
 
4